Dishman Carbogen Amcis Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹851Cr
- +18.9% YoY
- +18.2% QoQ
- Net profit
- ₹22Cr
- −48.8% YoY
- Turned profitable QoQ
- Margin
- 19%
- −2 pp YoY
- +3 pp QoQ
Guidance rank: #82 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
2 of 5 strong
The short version
The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. Revenue CAGR expected at ~15% over the next 3 years, higher than previous years (Page 28).
From Dishman Carbogen Amcis Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. (Page 28)
- India business aims to grow significantly, targeting INR 500 crores revenue by FY28, benefiting from tech transfers and multiple projects in the pipeline. (Pages 12, 18, 23)
- Stand-alone India revenue expected to increase in FY27 versus FY26, with potential to reach or exceed FY25 levels (~INR 400 crores) and grow further in FY28. (Page 19)
- CDMO segment to maintain approximately 85% share of revenues and grow steadily; marketable molecules about 15%. (Page 16)
- Margins in both CDMO and marketable molecule segments expected to improve, targeting 25% EBITDA margin by FY28. (Page 15)
2 more points from Dishman Carbogen Amcis Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major CapEx plans currently, except for co-investment with a Japanese innovator, where 100% of CapEx financing is by the partner (Page 18).
- Ongoing maintenance CapEx will continue group-wide.
- Investments planned in digital transformation, including SAP implementation across the group, lab management software, and exploring AI for process efficiencies (Page 18).
- The recent Swiss manufacturing line went live in Q4 FY25; no significant new fixed assets planned beyond current capacity (Page 9).
- Some CapEx may be required in the future, but not planned currently; financing sources considered cheap and flexible (Page 26).
2 more points from Dishman Carbogen Amcis Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company holds around INR 1,100 to INR 1,200 crores worth of Requests for Proposals (RFPs) in the India business.
- They expect to convert approximately 30-35% of these RFPs into firm orders.
- Physical inspection by a large innovator on a product’s active pharmaceutical ingredient is expected soon, which may translate into additional orders.
- New contracts and orders are in fluid stages; exact quarters of order fulfillment remain uncertain.
- For India, the target is to scale up revenue by INR 500 crores over the next 12 to 18 months.
2 more points from Dishman Carbogen Amcis Ltd's call on order book
Create a free account to keep reading this call
Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit
Dishman Carbogen Amcis Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 851 | 716 | +18.9% | 720 | +18.2% |
| Operating profit (EBITDA) | 163 | 153 | +6.5% | 113 | +44.2% |
| Operating margin | 19% | 21% | -2 pp | 16% | +3 pp |
| Profit before tax | 46 | 28 | +64.3% | -10 | — |
| Net profit (PAT) | 22 | 43 | -48.8% | -13 | — |
| EPS (₹) | 1.39 | 2.75 | -49.5% | -0.83 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹507 Cr, net loss ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dishman Carbogen's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dishman Carbogen Amcis Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dishman Carbogen Amcis Ltd Q4 FY26 results?
The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. Revenue CAGR expected at ~15% over the next 3 years, higher than previous years (Page 28).
What is Dishman Carbogen Amcis Ltd share price analysis?
Dishman Carbogen Amcis Ltd currently shows a below-average growth signal. The stock trades at a P/E of 164.8 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dishman Carbogen Amcis Ltd planning capital expenditure?
No major CapEx plans currently, except for co-investment with a Japanese innovator, where 100% of CapEx financing is by the partner (Page 18).
Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
